Stoke Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
STOK$27.21-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated statements of cash flows
Consolidated statements of cash flows
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(6,885) | $(88,981) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 1,770 | 2,177 |
| Amortization and accretion of marketable securities | (1,133) | (1,642) |
| Stock-based compensation | 32,238 | 27,470 |
| Impairment of right of use asset | 696 | — |
| Loss on disposal of property and equipment | 145 | — |
| Reduction in the carrying amount of right of use assets | 2,408 | 2,265 |
| Changes in assets and liabilities: | ||
| Accounts receivable | (4,268) | (50) |
| Prepaid expenses and other current assets | (545) | (1,786) |
| Accounts payable, accrued liabilities, and operating leases | 21,289 | 3,088 |
| Deferred revenue | (130) | (29,392) |
| Net cash provided by (used in) operating activities | 45,585 | (86,851) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (670) | (203) |
| Purchases of marketable securities | (322,722) | (167,272) |
| Sales of marketable securities | 136,580 | 60,000 |
| Net cash used in investing activities | (186,812) | (107,475) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock upon exercise of stock options | 8,603 | 1,722 |
| Proceeds from employee stock purchase plan | 1,002 | 532 |
| Proceeds from controlled equity offering sales agreement, net of commissions | 87,784 | 8,956 |
| Proceeds from follow-on offering, net of underwriting discounts, commissions and offering costs | — | 119,884 |
| Net cash provided by financing activities | 97,389 | 131,094 |
| Net decrease in cash, cash equivalents and restricted cash | (43,838) | (63,232) |
| Cash, cash equivalents and restricted cash—beginning of year | 128,779 | 192,011 |
| Cash, cash equivalents and restricted cash—end of year | $84,941 | $128,779 |
| Supplemental Disclosure of Non-Cash Investing and Financing Activities: | ||
| Right-of-use assets recognized in exchange for operating leases | $1,776 | $— |
| Property and equipment included in accrued expense and accounts payable | $482 | $61 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.